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Abstract 
Background: Modified response evaluation criteria in solid tumors (mRECIST) and RECIST are used to assess the 
effect of treatment with targeted agents for hepatocellular carcinoma (HCC). The aim of this study was to determine 
which set of criteria is superior in patients with advanced HCC treated with sorafenib.
Methods: A multicenter retrospective study to assess the tumor response and patient prognosis of 191 patients with 
HCC who had been treated with sorafenib from May 2009 through December 2011. We analyzed tumor responses as 
shown by contrast-enhanced computed tomography scan images according to RECIST 1.1 and mRECIST and com-
pared the findings.
Results: The median duration of follow-up was 9.7 months and median overall survival was 10.8 months. Twenty-
five patients (13.1 %) were assessed as responders by mRECIST and 15 (7.8 %) by RECIST 1.1. There was a significant 
difference in overall survival (OS) between responders and non-responders according to mRECIST (P = 0.0117), but 
no significant difference in OS between responders and non-responders according to RECIST 1.1 (P = 0.0722). Sixteen 
patients (8.4 %) had no measurable enhanced target lesions that could be assessed as required by mRECIST; how-
ever, these patients could be assessed by RECIST 1.1. According to RECIST 1.1, eight of them had stable disease (SD) 
and eight had progressive disease (PD). There was a significant difference in OS between these SD and PD patients 
(P = 0.0312).
Conclusions: Patients treated with sorafenib for HCC should be evaluated by mRECIST; RECIST 1.1 is preferable only 
for assessment of patients with lesions that are non-measurable according to mRESIST.
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Background
The Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol (SHARP) trial and phase III study 
conducted in the Asia–Pacific region proved survival 
benefits and good tolerability in the USA, Europe, and 
Asia–Pacific regions [1, 2]. Therefore, the current guide-
lines for the management of hepatocellular carcinoma 
(HCC) recommend sorafenib as first-line treatment for 
patients with advanced disease and well-preserved liver 
function (Child-Pugh A class) and state that there is no 
effective second-line treatment after sorafenib therapy; 
development of new regimens is required [3, 4].
Overall survival (OS) is the major endpoint used when 
investigating new treatment regimens for HCC and 
other cancers. Because earlier endpoints such as time 
to progression (TTP), progression-free survival (PFS), 
and response rate are used as guides for the early deter-
mination of whether to continue a particular therapy, 
these endpoints are appropriate in phase II trials, which 
aim at determining whether to launch larger scale clini-
cal trials [5]. Response evaluation criteria in solid tumors 
(RECIST) is a well-established means of assessing tumor 
response and is used with confidence worldwide [6]; 
however, it was designed for assessing responses to cyto-
toxic agents and does not address measures of antitu-
mor activity other than tumor shrinkage [7]. The use of 
RECIST to determine response rates to the treatment of 
HCC is controversial, especially when evaluating agents 
that reduce tumor vascularity and cell proliferation, 
resulting in stabilization of sizes of tumors despite central 
necrosis [5, 8, 9]. Thus, although sorafenib significantly 
improves OS compared with placebo, the response rate 
according to RECIST is only 2.0–3.3 % [1, 2].
Objective and precise criteria for evaluating treatment 
are required to determine whether to continue a par-
ticular treatment for HCC. A panel of experts on HCC 
convened by the European Association for the Study of 
the Liver (EASL) has therefore amended the response 
criteria to take tumor necrosis into account [10]. They 
recommended using contrast-enhanced radiologic imag-
ing to identify viable lesions, which they defined as 
those that take up contrast agent in the arterial phase of 
dynamic studies, thus more accurately assessing treat-
ment response [10]. As a result of their recommendations, 
a group from the American Association for the Study of 
Liver Diseases provided a common framework for clini-
cal trials in patients with HCC by modified the RECIST 
guidelines (mRECIST), including incorporating the con-
cept of viable tumor proposed by the EASL guidelines [8].
Some studies evaluating treatment responses to tar-
geted agents have reported that mRECIST identifies 
more treatment responders and stratifies for OS better 
than RECIST in patients treated with sorafenib. However, 
these studies were not large (53–66 patients) [11–13]. 
Additionally, by drawing on data from a large database 
(>6500 patients), simulation studies, and reviews of pub-
lished reports, RECIST has been further modified to pro-
duce the current revised RECIST version 1.1 (RECIST 
1.1) [14].
The aim of this study was to identify the most appropri-
ate assessment criteria for evaluating sorafenib treatment 
for HCC. To achieve this, we assessed the associations 
between responses as evaluated by conventional RECIST 
1.1 and mRECIST and survival data to determine which 
criteria more accurately identified responders and pre-
dicted prognoses of responding patients.
Methods
Study design and selection of patients
This multicenter, retrospective, observational study 
aimed to assess tumor responses and prognoses of 
patients with HCC treated with sorafenib at four insti-
tutes of the Kanagawa Liver Study Group in Japan. The 
primary endpoint was to compare the ability of RECIST 
1.1 and mRECIST to predict prognosis. All data, includ-
ing patients’ histories, clinical characteristics, laboratory 
data, and radiological information were collected retro-
spectively from each institution.
The common eligibility criteria were as follows: (1) 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) score of two or less; (2) Child–Pugh 
liver function class A or B; and (3) aged 20 years or older. 
The exclusion criteria were as follows: (1) previously 
treated with molecular-targeted therapies; (2) not treated 
with a single agent; (3) curative surgery performed after 
sorafenib treatment; and (4) responses to treatment not 
assessed by computed tomography (CT) scan.
This retrospective study was approved by the Ethical 
Committee of the Kitasato University (Kanagawa, Japan).
Diagnosis
All patients had at least one index lesion measuring 1 cm 
or larger in diameter (i.e., a target lesion) at baseline. 
Confirmation of the diagnosis of HCC was obtained by 
observing the typical features of arterial enhancement 
followed by washout during the portal venous phase on 
dynamic scan or pathologically based on the American 
Association for the Study of Liver Diseases guidelines [4].
Treatment regimens
Patients in this study were treated with sorafenib (Nex-
avar, Bayer Healthcare Pharmaceuticals) orally as a 
monotherapy. The standard dose was 400  mg (consist-
ing of two 200 mg tablets) twice daily. Treatment inter-
ruptions and dose reductions (first 400  mg twice daily, 
then 400 mg once daily, and finally 400 mg every 2 days) 
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were permitted for adverse events. In some patients 
who had poor liver function or were aged ≥75 years, the 
initial dose was only half of the standard dose (400 mg 
once daily). The following were assessed as treatment 
failure: (1) an unmanageable adverse event that required 
termination of therapy; (2) disease progression (accord-
ing to either RECIST 1.1 or mRECIST); (3) liver func-
tion dwindled to Child-Pugh class C; (4) deterioration of 
ECOG PS score to four; and (5) withdrawal of consent to 
therapy.
CT scan protocol
CT images were obtained after injection of 100–135 mL 
of iodine contrast (300 or 350 mg/mL) at an average flow 
rate of 3.0 mL/s using an automatic power injector. Slice 
collimation was 5 mm in the arterial and portal phases. 
Arterial phase imaging was performed 15–19  s after 
achievement of 200 HU attenuation of the descending 
aorta measured using a bolus tracking method. There 
was a 30- to 35-s delay between the arterial phase and 
portal venous phase acquisition.
Evaluation of treatment response
Tumor measurements were performed on CT scans 
obtained within 1 month of commencing treatment and 
every 1–2 months during treatment.
Tumor responses were evaluated separately accord-
ing to the best response according to RECIST 1.1 and 
mRECIST in a non-blinded fashion, by an oncologist 
and a radiologist who were both specialists in liver 
cancer. The target lesions were defined by both physi-
cians on their pretreatment CT scans of all patients. 
Each physician then made separate measurements and 
determined the tumor responses. In cases of disagree-
ment, a consensus was reached. Target lesions were 
defined as the whole lesion for RECIST assessment 
and as the contrast-enhanced portion of the lesion in 
the arterial phase for mRECIST assessment. For evalu-
ation according to RECIST, complete response (CR) 
was defined as the absence of all target lesions; partial 
response (PR) and progressive disease (PD) as a greater 
than 30  % decrease and a greater than 20  % increase, 
respectively, in the sum of the longest diameters of 
the target lesions; and stable disease (SD) as neither 
PR nor PD [14]. However, for evaluation according to 
mRECIST, CR was defined as the absence of arterially 
enhanced areas in all target lesions; PR and PD as the 
same degree of decrease and increase as in the RECIST 
criteria, these sums being those of the diameters of 
arterial enhanced areas in all target lesions rather than 
the sums of the diameters of the whole target lesions 
size; and SD as neither PR nor PD. When evaluating 
according to mRECIST, patients with no enhanced 
lesions were classified as non-measurable. The greatest 
variation (maximum decrease or minimum increase) 
in the sum of the greatest lesion dimensions for each 
patient were also recorded [3, 8].
Adverse events were graded according to the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse events, version 3.0 or 4.0.
Identification of target and non‑target lesions
At baseline, target lesions were defined as those largest 
diameters of 1 cm or more and non-target lesions as those 
with largest diameters of <1 cm. In accordance with RECIST 
1.1 recommendations, a maximum of two lesions per organ 
and five lesions in total were selected for assessment of 
treatment response [6]. The same number of lesions were 
selected for assessment by mRECIST. Macroscopic vascular 
invasions were considered as non-target lesions. Extrahe-
patic lesions were considered as target lesions. Lesions with 
no arterial enhancement that were therefore not measurable 
by mRECIST were considered as non-target lesions when 
evaluating by mRECIST only [3, 8, 13].
Statistical analysis
Continuous variables are presented as medians and 
ranges and categorical variables as percentages. Between-
group comparisons of variables were performed using the 
Mann–Whitney U test for continuous variables and the 
Chi square or Fisher’s exact test for categorical variables. 
Survival times were measured from the start of sorafenib 
initiation. OS ended at the time of death or was cen-
sored at the time of the last follow-up visit. Duration of 
sorafenib treatment ended at the time of the last admin-
istration of sorafenib for any reason or was censored at 
the time of the last follow-up visit. Survival analyses were 
performed using the Kaplan–Meier method and com-
pared using the log-rank test. A Cox proportional hazards 
model was used to determine independent prognostic 
factors for OS after adjustment for confounding factors. 
All reported P values are two-sided, P values <0.05 being 
considered statistically significant. Dr SPSS Base 11.0j 
(SPSS Inc., Chicago, IL, USA) for Windows was used to 
perform all computations, and two-tailed P values <0.05 
were considered to indicate statistical significance.
Results
Patients and baseline characteristics
Figure  1 shows a flow diagram of patient recruitment 
for this study. Between May 2009 and December 2011, 
254 patients underwent sorafenib treatment at four 
institutes of the Kanagawa Liver Study Group. Of these 
254 patients, 63 were excluded, 19 (9.9 %) because they 
had received concomitant treatment (16 with radio-fre-
quency ablation, two with cytotoxic agents, and one with 
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radiotherapy) and 44 (23 %) because post-treatment CT 
scans had not been performed (because of death in 29 
patients and worsening of PS in 15). Thus, 191 patients 
were finally included in the current study. Treatments 
prior to sorafenib were as follows; surgical resection in 
11 patients, percutaneous locoregional treatments in 20, 
arterial chemoembolization in 117, arterial chemother-
apy in 16, systematic chemotherapy in two, and internal 
radiation in seven. Eighteen patients had not undergone 
any treatment before sorafenib.
Baseline characteristics are shown in Table  1. The 
standard dosage of sorafenib was initially administered 
to 126 patients (66 %) and the half-dose regimen to the 
remaining 65 (34 %).
Safety and tolerability
The median duration of follow-up in this cohort 
was 9.7  months [range 1.0–31.9  months; 95  % confi-
dence interval (95  % CI) 8.2–11.2]. The median dura-
tion of sorafenib treatment was 2.0  months (range 
0.7–12.5  months; 95  % CI 1.9–2.1). Seventy-three 
patients (38  %) stopped sorafenib treatment because of 
adverse events, 83 (43 %) because of disease progression 
and one patient was censored for changing anticancer 
agent before disease progression. Table  2 shows drug-
related adverse events.
Treatment responses
Table  3 shows the best responses as assessed by both 
RECIST 1.1 and mRECIST. According to RECIST 1.1, 
the response rate (defined as the percentage of CR or 
PR patients) was 7.8 % (15/191) and the disease control 
rate (defined as percentage of CR +  PR +  SD patients) 
was 53.4 % (102/191). However, according to mRECIST, 
the response rate was 14.3  % (25/191) and the disease 
control rate 55.4 % (106/191). Evaluation of response to 
treatment by RECIST1.1 and mRECIST corresponded 
in 162 patients (84.8  %) (CR/PR/SD/PD: 4/11/70/77, 
respectively). Ten patients evaluated as non-responders 
by RECIST1.1 were evaluated by mRECIST as respond-
ers (one patient’s response changed from SD to CR, eight 
from SD to PR, and one from PD to PR). Sixteen patients 
were not evaluated by mRECIST because they had no 
measurable target lesions (no enhanced lesions). Eight of 
these patients were evaluated by RECIST1.1 as having SD 
and eight as PD.
Fig. 1 Flow diagram of study enrollment
Page 5 of 10Takada et al. BMC Res Notes  (2015) 8:609 
Survival analysis
In all, 120 patients (62.8  %) died during the study 
period. The median OS was 10.8  months (range 1.0–
31.9  months; 95  % CI 9.6–12.0) and the 1-year survival 
rate was 44.8 %. Figures 2 and 3 show OS curves for the 
four response categories as evaluated by RECIST1.1 
and mRECIST, whereas Figs.  4 and 5 show a compari-
son of OS for responders and non-responders as evalu-
ated by RECIST 1.1 and mRECIST. Patients classified 
as responders by mRECIST had significantly better OS 
than non-responders (Fig.  5; P =  0.0117). However, the 
OS of those classified as responders by RECIST1.1 did 
not differ significantly from that of non-responders 
(Fig. 4). Although the treatment responses of 16 patients 
(8.4 %) could not be assessed by mRECIST because they 
had no enhanced lesions (Table  3), eight of them were 
assessed as SD and eight as PD by RECIST1.1. These 
subgroups had significantly different OS (Fig. 6; median 
OS  =  13.7  months versus 5.7  months, respectively; 
P = 0.0312).
Discussion
In this study, we compared assessment of response to 
sorafenib by RECIST 1.1 and mRECIST in patients with 
Table 1 Baseline characteristics of study subjects
AFP alpha-fetoprotein, BCLC Barcelona clinic liver cancer stage, DCP des-
gamma carboxy prothrombin, ECOG Eastern Cooperative Oncology Group, HB 
hepatitis B virus, HC hepatitis C virus, NBNC non-B and non-C hepatitis virus, PS 
performance status
Characteristics Study cohort (n = 191)
Age (years): median (range) 72 (34–88)
Male gender: no. (%) 149 (78)
Cause of liver disease: no. (%)
 HC 112 (59)
 HB 35 (18)
 HC + HB 4 (2)
 Others 40 (21)
Child–Pugh class: no. (%)
 A/B 179/12 (94/6)
ECOG PS: no. (%)
 0 141 (74)
 1 47 (25)
 2 3 (1)
BCLC stage: no. (%)
 A 11 (6)
 B 85 (44)
 C 95 (50)
Prior treatment: no. (%)
 Resection 13 (7)
 Radio frequency ablation 22 (11)
 Transarterial chemoembolization 137 (72)
 None 19 (10)
Macroscopic vascular invasion: no. (%) 51 (27)
Extrahepatic spread: no. (%) 56 (29)
Reduced initiation dose: no. (%) 65 (34)
Laboratory data: median (range)
 Hemoglobin (g/dL) 12.5 (7.7–18.0)
 Platelet count (104/μ) 12.3 (3.5–47.5)
 Aspartate aminotransferase (IU/L) 55 (13–354)
 Alanine aminotransferase (IU/L) 44 (10–238)
 Albumin (g/dL) 3.7 (2.4–4.7)
 Total bilirubin (mg/dL) 0.8 (0.3–2.6)
 AFP (ng/mL) 81 (1.6–409,000)
 DCP (mAU/mL) 332 (8–893,000)
Table 2 Drug-induced adverse events according to  the 
common terminology criteria for  adverse events version 
3.0 or 4.0
ALT alanine aminotransferase, AST aspartate aminotransferase
All grades Grade 3 or 4
No. (%) No. (%)
Adverse events 181 (94.8) 103 (53.9)
Hand-foot skin reaction 120 (62.8) 38 (19.9)
Elevated AST 114 (59.7) 26 (13.6)
Elevated ALT 103 (53.9) 14 (7.3)
Fatigue 98 (51.3) 13 (6.8)
Appetite loss 84 (44.0) 20 (10.5)
Diarrhea 76 (39.8) 12 (6.3)
Hypertension 73 (38.2) 11 (5.8)
Skin rash 40 (20.9) 5 (2.6)
Voice changes 23 (12.0) 2 (1.0)
Alopecia 23 (12.0) 0 (0.0)
Gastrointestinal bleeding 4 (2.1) 1 (0.5)
Variceal bleeding 3 (1.6) 2 (1.0)
Table 3 Treatment evaluation according to  response 
evaluation criteria in  solid tumors (RECIST) version 1.1 
and modified (m) RECIST
CR complete response, PD progressive disease, PR partial response, SD stable 
disease
RECIST 1.1 Total (mRECIST)
CR PR SD PD
mRECIST
 CR 4 0 1 0 5
 PR 0 11 8 1 20
 SD 0 0 70 2 72
 PD 0 0 1 77 78
 Non-measurable 0 0 8 8 16
Total (RECIST 1.1) 4 11 88 88 191
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advanced HCC to determine which criteria more accu-
rately predict prognosis. Although we found that both 
RECIST1.1 and mRECIST could distinguish PD group 
from controlled disease, mRECIST identified approxi-
mately double the number of responders that RECIST 
1.1 did; consequently, the response rate according to 
mRECIST exceeded 10  % whereas that determined by 
RECIST 1.1 did not. Responders according to mRECIST 
had a significantly better OS than nonresponders; this 
was not true for RECIST. The potential benefits of the 
more accurate identification of responders by mRECIST 
include the following: (1) a partial response to therapy 
can serve as a surrogate marker of clinical benefit [7, 15]; 
and (2) response rates exceeding 10 % in phase II studies 
of single-agent non-cytotoxic drug therapy are generally 
an indicator of survival advantages in phase III stud-
ies [7]. Therefore, we believe that mRECIST is superior 
to RECIST 1.1 for assessing antitumor effects in phase II 
studies of targeted therapies for HCC.
This study showed a good overall response rate to 
sorafenib (CR  +  PR; 7.8  %) compared with published 
prospective trials (2.0–3.3  %) [1, 2]. However, in one 
study, 9.6 % of Japanese patients with HCC treated with 
sorafenib were reportedly classified by RECIST1.1 as 
responders [16]; these authors suggested there may 
be a racial difference concerning gene mutations that 
influence the response rate, similar to the epidermal 
growth factor receptor mutation for gefitinib [17].
A number of previous clinical studies of HCC treat-
ment have demonstrated that RECIST criteria, which 
do not reflect tumor vascularization, do not accurately 
mirror the extent of tumor necrosis induced by chem-
oembolization, transcatheter chemotherapies, and percu-
taneous locoregional therapies [18–20]. These treatments 
can be demonstrated to have conferred benefit if tumor 
vascularization is taken into account by identifying via-
ble tumor by its enhancement with contrast agent in the 
arterial phase of a dynamic CT [8]. Llovet et al. claimed 
that assessment of reduction in volume of viable tumor 
using contrast-enhanced radiological imaging is the opti-
mal means of assessing treatment response [5]. Thus, 
MRECIST is more accurate than RECIST for evaluating 
responses of HCC, which are commonly hypervascular.
According to mRECIST, non-enhanced tumor is 
not measurable. Assessment of such lesions is impor-
tant because evaluation of response may otherwise be 
incomplete. Among several additional radiologic crite-
ria aimed at evaluating tumor viability after treatment 
with targeted agents, Choi et  al. proposed basing such 
criteria on target density as determined by measur-
ing the CT attenuation coefficient; this approach could 
be useful for evaluating HCC treatment [13, 21–25]. 
Fig. 2 Kaplan–Meier analysis of overall survival. The log-rank test showed significant differences between the four groups (P < 0.0001) categorized 
according to RECIST 1.1
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Fig. 3 Kaplan–Meier analysis of overall survival. The log-rank test showed significant differences between the four groups (P < 0.0001) categorized 
according to mRECIST
Fig. 4 Kaplan–Meier analysis of overall survival. The log-rank test did not show significant differences between responders and non-responders 
classified according to RECIST 1.1 (P = 0.0722)
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Fig. 5 Kaplan–Meier analysis of overall survival. The log-rank test showed significant differences between responders and non-responders classified 
according to mRECIST (P = 0.0117)
Fig. 6 Kaplan–Meier analysis of overall survival in small cohort of patients with non-measurable lesions by mRECIST (n = 16). The log-rank test 
showed significant differences between progressive disease (PD) (n = 8) and stable disease (SD) groups (n = 8) as determined by RECIST 1.1 
(P = 0.0312)
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However, our subgroup analysis indicated that assess-
ment by conventional RECIST adequately predicts 
prognosis in patients with non-enhancing atypical 
lesions without using Choi’s criteria because, as Llovet 
at el. reported, the conventional RECIST criteria are 
applicable to non-enhancing atypical lesions [5]. How-
ever, measurement of the size of the tumor alone has 
limitations because it cannot distinguish tumor pro-
liferation from necrosis, as previously described [26]. 
Additionally, magnetic resonance imaging and meas-
urement of serum alfa-fetoprotein levels are useful for 
clinical evaluation of non-enhancing atypical lesions 
and may differentiate tumor proliferation from necrosis 
in such tumors [12, 21, 27–30].
Limitations
In this multicenter retrospective study, post-sorafenib 
treatment and reduction in dosage of sorafenib were 
not standardized. In addition, assessment of response to 
treatment may have varied according to the CT scan pro-
cedures and interpretations in each institute. However, 
we believe that our findings do reflect clinical outcomes 
of both sets of criteria because this multicenter study 
was able to enroll many more patients than previously 
reported studies [11–13].
Conclusions
Patients treated with sorafenib for HCC should be eval-
uated by mRECIST; RECIST 1.1 is preferable only for 
assessment of patients with lesions that are non-measur-
able according to mRECIST.
Abbreviations
CI: confidence interval; CR: complete response; CT: computed tomogra-
phy; EASL: European Association for the Study of the Liver; ECOG: Eastern 
Cooperative Oncology Group; HCC: hepatocellular carcinoma; mRECIST: 
modified response evaluation criteria in solid tumors; OS: overall survival; PFS: 
progression-free survival; PD: progressive disease; PR: partial response; PS: 
performance status; RECIST: response evaluation criteria in solid tumors; SD: 
stable disease; SHARP: The Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol; TTF: time to treatment failure; TTP: time to progression; 
TTS: time to treatment stop.
Authors’ contributions
HH conceived the study. JT, HH, TN, MK, KN, KT, KM, CO, MM, SK, and SO 
designed the study and collected clinical data. JT and HH analyzed the data 
and drafted the article. TN, KT, and WK revised the article critically. All authors 
read and approved the final manuscript.
Author details
1 Department of Gastroenterology, Internal Medicine, Kitasato University 
Hospital, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, 
Sagamihara, Kanagawa 252-0375, Japan. 2 Department of Gastroenterological 
Center, Yokohama City University Medical Center, Yokohama, Japan. 3 Depart-
ment of Gastroenterology and Hepatology, St Marianna University School 
of Medicine, Kawasaki, Japan. 4 Hepatobiliary and Pancreatic Medical Oncol-
ogy, Kanagawa Cancer Center Hospital, Yokohama, Japan. 
Acknowledgements
With regard to sorafenib-related data collection, the authors would like to 
thank the following colleagues of the Kanagawa Liver Study Group: Michihiro 
Suzuki of the Gastroenterology and Hepatology, Department of Internal 
Medicine, St Marianna University School of Medicine; and Tsutomu Minamino, 
Yoshiaki Tanaka, Yusuke Okuwaki, Akitaka Shibuya from the Kitasato University 
School of Medicine. We also thank Department of Gastroenterology, Kitasato 
University School of medicine for its financial support.
Competing interests
The authors declare that they have no competing interests.
Received: 5 April 2014   Accepted: 5 October 2015
References
 1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP 
Investigators Study Group. Sorafenib in advanced hepatocellular carci-
noma. N Engl J Med. 2008;359:378–90.
 2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and 
safety of sorafenib in patients in the Asia-Pacific region with advanced 
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-
controlled trial. Lancet Oncol. 2009;10:25–34.
 3. European Association for the Study of the Liver, European Organisation 
for Research and Treatment of Cancer. EASL–EORTC clinical practice 
guidelines: management of hepatocellular carcinoma. J Hepatol. 
2012;56:908–43.
 4. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: an 
Update. Hepatology. 2011;53:1020–2.
 5. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, 
et al. Panel of experts in HCC-design clinical trials: design and end-
points of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 
2008;100:698–711.
 6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein 
L, et al. New guidelines to evaluate the response to treatment in solid 
tumors. J Natl Cancer Inst. 2000;92:205–16.
 7. Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct 
of cancer clinical trials. Eur J Cancer. 2006;42:1322–30.
 8. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepato-
cellular carcinoma. Semin Liver Dis. 2010;30:52–60.
 9. Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of 
new cancer treatments: challenges and opportunities. Nat Rev Cancer. 
2003;3:303–9.
 10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, 
et al. EASL panel of experts on HCC: clinical management of hepatocel-
lular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J 
Hepatol. 2001;35:421–30.
 11. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. 
Comparison of tumor response by response evaluation criteria in solid 
tumors (RECIST) and modified RECIST in patients treated with sorafenib 
for hepatocellular carcinoma. Cancer. 2012;118:147–56.
 12. Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, et al. 
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the 
prognosis of advanced-hepatocellular-carcinoma patients treated with 
sorafenib. Oncology. 2012;83:192–200.
 13. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque 
B, et al. Alternative Response Criteria (Choi, European association for 
the study of the liver, and modified Response Evaluation Criteria in 
Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced 
hepatocellular carcinoma treated with sorafenib. Oncologist. 
2014;19:394–402.
 14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, 
et al. New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
 15. Karnofsky DA. Meaningful clinical classification of therapeutic responses 
to anticancer drugs. Clin Pharmacol Ther. 1961;2:709–12.
Page 10 of 10Takada et al. BMC Res Notes  (2015) 8:609 
 16. Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, et al. Compari-
son of systems for assessment of post-therapeutic response to sorafenib 
for hepatocellular carcinoma. J Gastroenterol. 2014;49:1578–87.
 17. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, 
in the treatment algorithm for hepatocellular carcinoma and implication 
of many complete remission cases in Japan. Oncology. 2010;78:154–66.
 18. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. 
Evaluation of tumor response after locoregional therapies in hepatocel-
lular carcinoma: are response evaluation criteria in solid tumors reliable? 
Cancer. 2009;115:616–23.
 19. Kim SK, Lim HK, Kim YH, Lee WJ, Lee SJ, Kim SH, et al. Hepatocellular 
carcinoma treated with radio-frequency ablation: spectrum of imaging 
findings. Radiographics. 2003;23:107–21.
 20. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. 
Imaging response in the primary index lesion and clinical outcomes 
following transarterial locoregional therapy for hepatocellular carcinoma. 
JAMA. 2010;303:1062–9.
 21. Horger M, Lauer UM, Schraml C, Berg CP, Koppenhöfer U, Claussen 
CD, et al. Early MRI response monitoring of patients with advanced 
hepatocellular carcinoma under treatment with the multikinase inhibitor 
sorafenib. BMC Cancer. 2009;9:208.
 22. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel 
SR, et al. Correlation of computed tomography and positron emission 
tomography in patients with metastatic gastrointestinal stromal tumor 
treated at a single institution with imatinib mesylate: proposal of new 
computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.
 23. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen 
LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 
2007;25:1760–4.
 24. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, 
et al. Measurement of clinical and subclinical tumour response using 
[18F]-fluorodeoxyglucose and positron emission tomography: review 
and 1999 EORTC recommendations. European Organization for Research 
and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 
1999;35:1773–82.
 25. Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, et al. 
Changes in tumor density in patients with advanced hepatocellular 
carcinoma treated with sunitinib. Clin Cancer Res. 2011;17:4504–12.
 26. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani 
F, et al. Usefulness of alpha-fetoprotein response in patients treated 
with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 
2012;57:101–7.
 27. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised 
RECIST guideline version 1.1: what oncologists want to know and what 
radiologists need to know. AJR Am J Roentgenol. 2010;195:281–9.
 28. Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, et al. 
Early increase in α-fetoprotein for predicting unfavorable clinical out-
comes in patients with advanced hepatocellular carcinoma treated with 
sorafenib. Eur J Gastroenterol Hepatol. 2013;25:683–9.
 29. Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, et al. Early 
decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts 
sorafenib efficacy in patients with advanced hepatocellular carcinoma. 
Oncology. 2011;81:251–8.
 30. Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of 
early alpha-fetoprotein level changes in predicting clinical and survival 
benefits in advanced hepatocellular carcinoma patients receiving 
sorafenib. Oncologist. 2011;16:1270–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
